Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Heart Failure, High Blood Pressure, High Cholesterol, Anemia, Diabetes, Thyroid Diseases, Kidney Diseases, Clotting Disorder, Trauma, Other Disease
Interventions: BVA-200; Diagnostic Test
Lead sponsor: Daxor Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Oak Ridge, Tennessee

Conditions: Hypertension
Interventions: Booster/ low resource, Medium/Level 1 resource intensity, High/Level 2 resource intensity; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pulmonary Hypertension
Interventions: Carvedilol, placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pregnancy Induced Hypertension, Superimposed Preeclampsia, Hypertension
Interventions: Nicotinamide 500 mg, Nicotinamide 1000 mg; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Portal Hypertension
Interventions: Placebo, Cobiprostone; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Glaucoma
Interventions: Silicone plate Ahmed Glaucoma Valve (Model FP7), Porous Plate Ahmed Glaucoma Valve (Model M4); Device
Lead sponsor: Peter Netland, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hypertension, Diabetes Mellitus
Interventions: CVRS Intervention; Behavioral
Lead sponsor: Korey Kennelty; Other
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 14
States / cities: Pocatello, Idaho • Chicago, Illinois • Mahomet, Illinois + 11 more

Conditions: Post Partum Pain
Interventions: NSAID use; Other
Lead sponsor: St. Louis University; Other
Eligibility: 12 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pulmonary Arterial Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more

Conditions: Hypertension
Interventions: High dietary sodium intake, Low dietary sodium intake; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: San Diego, California

Conditions: Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions: EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypertension, Blood Pressure
Interventions: The Vital Labs Digital Blood Pressure Monitor; Device
Lead sponsor: Riva Health; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 343 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: San Francisco, California • Walnut Creek, California • Aurora, Colorado

Conditions: Pulmonary Hypertension, Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions: Nebivolol; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 6 Years to 17 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Hypertension in the Obstetric Context
Interventions: Antihypertensive Agents; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Hypertension in Pregnancy, Preeclampsia
Interventions: Nifedipine, Labetalol; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Brooklyn, New York • New York, New York

Conditions: Type 2 Diabetes Mellitus, Cardiovascular Disease, Hypertension, Inadequate Glycaemic Control
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 45 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 60
States / cities: Gulf Shores, Alabama • Phoenix, Arizona • Burbank, California + 57 more

Conditions: Preeclampsia and Eclampsia, Preeclampsia Severe, Gestational Hypertension, Chronic Hypertension in Obstetric Context, Superimposed Pre-Eclampsia, Preeclampsia Mild
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 13 more

Conditions: Hypertension
Interventions: Hypertension Coaching Application and Home Monitor, Control: Tracking Application and Home Monitor; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glaucoma
Interventions: Brimonidine, Placebo Lotion; Drug
Lead sponsor: Nanduri, Padma, M.D., FACS; Individual
Eligibility: 21 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Visalia, California

Conditions: Hypertension
Interventions: ramipril; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • Augusta, Georgia + 22 more

Conditions: Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
Interventions: GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm); Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio + 1 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Persistent Fetal Circulation Syndrome, Persistent Pulmonary Hypertension of Newborn
Interventions: Not listed
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 7 Days
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1994
U.S. locations: 13
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more

Conditions: Hypertension
Interventions: Interactive Spaced Education (ISE) --- online education; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Brockton, Massachusetts

Search by objective public record fields.

BVA-200 vs BVA-100 Validation Study

Titrated Disease Management for Patients With Hypertension

PAHTCH Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure (Carvedilol)

Phase I Study of Nicotinamide for Early Onset Preeclampsia

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves

Dissemination of the Cardiovascular Risk Service

Retrospective Review of NSAIDS in the Postpartum Period

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

Human Sodium Balance Study

Topical Insulin for Glaucoma (TING2)

VL-3 Training Study

Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure

Improving Outcomes for Hypertensive Children

Postpartum Hypertension, Tight vs Liberal Control Trial

Response to Anti-hypertensives in Pregnant and Postpartum Patients

Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension

Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification

The Smart Hypertension Control Study

Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy

Treatment of Pediatric Hypertension With Altace Trial

VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)

Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study

Interactive Spaced Education to Optimize Hypertension Management